FAMVIR 125 MG — DIN 02229110
FAMCICLOVIR : 125 MG · SEARCHLIGHT PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is FAMVIR?
FAMVIR 125 MG contains FAMCICLOVIR : 125 MG. It is listed in the Health Canada Drug Product Database under DIN 02229110, held by SEARCHLIGHT PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Feb-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FAMVIR used for?
FAMVIR® (famciclovir) tablets are indicated for the treatment of acute herpes zoster (shingles), for the treatment or suppression of recurrent episodes of genital herpes in immunocompetent adults, and for the treatment of recurrent episodes of mucocutaneous herpes simplex infections in HIV-infected patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Famciclovir cost around the world?
Famciclovir is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 7 | 26 | AUD███.██ |
| United States | acquisition | 3 | 18 | USD███.██ |
| Italy | prezzo al pubblico (classe A) | 8 | 12 | EUR███.██ |
| Spain | PVP con IVA (public price) | 9 | 9 | EUR███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| South Africa | single exit price | 5 | 6 | ZAR███.██ |
| Saudi Arabia | public | 3 | 4 | SAR███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| Bahrain | retail (max) | 1 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
90 pack listings across 48 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Famciclovir pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Famciclovir in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Famciclovir, across 36 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 3 | 3 | APO-FAMCICLOVIR | Sourceable in Canada |
| SEARCHLIGHT PHARMA INC | 3 | 3 | FAMVIR | Sourceable in Canada |
| AURO PHARMA INC | 3 | 0 | AURO-FAMCICLOVIR | No marketed DIN |
| AVANSTRA INC | 3 | 0 | AVA-FAMCICLOVIR | No marketed DIN |
| COBALT PHARMACEUTICALS COMPANY | 3 | 0 | FAMCICLOVIR | No marketed DIN |
| DOMINION PHARMACAL | 3 | 0 | DOM-FAMCICLOVIR | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-FAMCICLOVIR | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-FAMCICLOVIR | No marketed DIN |
| PHARMEL INC | 3 | 0 | PHL-FAMCICLOVIR | No marketed DIN |
| PRO DOC LIMITEE | 3 | 0 | FAMCICLOVIR | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 3 | 0 | SANDOZ FAMCICLOVIR | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | ACT FAMCICLOVIR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 125 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 125 mg in blister packages of 10; 250 mg in bottles of 30 or 60 and in blister packages of 30; 500 mg in bottles of 30 or 60 and in blister packages of 21 |
| Storage | Store at controlled room temperature (15 - 25 °C). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Famciclovir |
|---|---|
| ATC code | J05AB09 |
| AHFS class | 08:18.32 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02229110 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2229110 |
| Brand name | FAMVIR |
| Generic / active ingredient | FAMCICLOVIR : 125 MG |
| Market authorization holder | SEARCHLIGHT PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | J05AB09 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AB |
| Current status | MARKETED |
| Status date | 13-Feb-2025 |
| Original market date | 1996-09-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 36 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FAMCICLOVIR | 125 MG | TABLET | APOTEX INC | MARKETED | 02292025 |
| APO-FAMCICLOVIR | 500 MG | TABLET | APOTEX INC | MARKETED | 02292068 |
| APO-FAMCICLOVIR | 250 MG | TABLET | APOTEX INC | MARKETED | 02292041 |
| FAMVIR | 500 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | 02177102 |
| FAMVIR | 250 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | 02229129 |
| ACT FAMCICLOVIR | 125 MG | TABLET | TEVA CANADA LIMITED | DORMANT | 02305682 |
| ACT FAMCICLOVIR | 500 MG | TABLET | TEVA CANADA LIMITED | DORMANT | 02305704 |
| ACT FAMCICLOVIR | 250 MG | TABLET | TEVA CANADA LIMITED | DORMANT | 02305690 |
| AURO-FAMCICLOVIR | 125 MG | TABLET | AURO PHARMA INC | APPROVED | 02431564 |
| AURO-FAMCICLOVIR | 250 MG | TABLET | AURO PHARMA INC | APPROVED | 02431572 |
2 · Same class — other molecules in ATC J05AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Valaciclovir | AG-VALACYCLOVIR · APO-VALACYCLOVIR · AURO-VALACYCLOVIR · BIO-VALACYCLOVIR · +17 more | 36 | 22 | Yes |
| Acyclovir | ACYCLOVIR · ACYCLOVIR SODIUM FOR INJECTION · ACYCLOVIR SODIUM INJECTION · ACYCLOVIR-200 · +17 more | 48 | 15 | Yes |
| Famciclovir | ACT FAMCICLOVIR · APO-FAMCICLOVIR · AURO-FAMCICLOVIR · AVA-FAMCICLOVIR · +7 more | 36 | 6 | Yes |
| Valganciclovir | APO-VALGANCICLOVIR · AURO-VALGANCICLOVIR · MINT-VALGANCICLOVIR · MYLAN-VALGANCICLOVIR · +3 more | 9 | 6 | Yes |
| Ganciclovir | CYTOVENE · CYTOVENE - CAP 250MG · CYTOVENE INJ 500MG/VIAL · CYTOVENE, 500 MG · +2 more | 9 | 4 | Yes |
| Remdesivir | VEKLURY | 2 | 1 | Yes |
| Cidofovir | MAR-CIDOFOVIR | 1 | 1 | Yes |
| Brincidofovir | TEMBEXA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is FAMVIR called?
The same molecule, Famciclovir, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Famciclovir | Latin | Australia |
| FAMCICLOVIR-WGR | Latin | Australia |
| Ezovir | Latin | Australia |
| Zostivr | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.